ACTG 175 was a randomized clinical trial to compare monotherapy with zidovudine or didanosine with combination therapy with zidovudine and didanosine or zidovudine and zalcitabine in adults infected with the human immunodeficiency virus type I whose CD4 T cell counts were between 200 and 500 per cubic millimeter.
data(ACTG175)A data frame with 6417 observations from 2139 patients on the following 24 variables.
patient ID number
age in years at baseline
weight in kg at baseline
hemophilia (0=no, 1=yes)
homosexual activity (0=no, 1=yes)
history of intravenous drug use (0=no, 1=yes)
Karnofsky score (on a scale of 0-100)
non-zidovudine antiretroviral therapy prior to initiation of study treatment (0=no, 1=yes)
zidovudine use in the 30 days prior to treatment initiation (0=no, 1=yes)
zidovudine use prior to treatment initiation (0=no, 1=yes)
number of days of previously received antiretroviral therapy
race (0=white, 1=non-white)
gender (0=female, 1=male)
antiretroviral history (0=naive, 1=experienced)
antiretroviral history stratification (1:antiretroviral naive, 2:greater than 1 but less than 52 weeks of prior antiretroviral therapy, 3: greater than 52 weeks)
symptomatic indicator (0=asymptomatic, 1=symptomatic)
treatment indicator (0=zidovudine only, 1=other therapies)
indicator of off-treatment before 96 weeks (0=no,1=yes)
missing CD4 T cell count at 96 weeks (0=missing, 1=observed)
indicator of observing the event in days
number of days until the first occurrence of: (i) a decline in CD4 T cell count of at least 50 (ii) an event indicating progression to AIDS, or (iii) death.
treatment arm (0=zidovudine, 1=zidovudine and didanosine, 2=zidovudine and zalcitabine, 3=didanosine)
time in weeks
CD4 T cell count
Hammer, S.M., et al. (1996), A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. New England Journal of Medicine, 335:1081-1090.